The safety record so far

Across clinical studies summarised in the manufacturer's April 2025 Clinical Evaluation Report (CER v09), ChondroFiller® liquid carries a reported complication rate of approximately 0% — a headline figure that stands in sharp contrast to the surgical alternatives it is most commonly weighed against. Microfracture carries a complication rate of up to 7% and a reoperation rate of up to 41%; autologous chondrocyte implantation and MACI procedures reach complication rates of up to 17% and reoperation rates of up to 37%. ChondroFiller®'s own reoperation rate of approximately 3–8%, while not trivial, sits well below both comparators.

These figures come primarily from manufacturer-sponsored data, and that context matters for interpretation. The CER draws on a pooled set of clinical studies rather than a single independent randomised controlled trial, so the numbers should be read as the best currently available evidence rather than definitive proof.

Independent corroboration comes from the Jerosch et al. prospective post-market clinical follow-up (PMCF) study, which reported no device-related serious adverse events over a three-year follow-up period. The same study recorded a mean IKDC improvement of 32.4 points sustained at three years — a meaningful functional gain alongside the clean safety signal.

Two evidence gaps are worth naming plainly: long-term safety data beyond three years remain limited, and independent randomised controlled trial data have not yet been published. The safety picture described here reflects what the current body of evidence supports — no more.

What ChondroFiller is made from

ChondroFiller® is derived from murine Type I collagen — that is, collagen sourced from mice. This is a material fact that should be raised and documented before any injection takes place. For most patients it carries no practical consequence, but anyone with a known sensitivity to rodent or animal proteins needs to disclose that history at their pre-injection consultation, since a theoretical immunogenic risk exists. The published clinical data have not prominently flagged adverse allergic events, yet proactive screening remains the responsible standard given the biological origin of the material.

The product is acellular: it contains no donor cells of any kind. Rather than delivering cells directly, the scaffold works by providing a chemotactic environment that draws the patient's own progenitor cells — migrating in from the surrounding synovium and subchondral bone — into the matrix, where they can differentiate and lay down new tissue. This process, known as acellular matrix-induced chondrogenesis, is gradual by design; it is the mechanism behind why improvements emerge over weeks to months rather than immediately after injection. Once placed in the joint, the collagen gel sets within a few minutes, stabilising the scaffold in position.

On the regulatory side, ChondroFiller® carries CE-marking as a Class III medical device under both EU and UK MDR — the highest-risk classification available. Reaching that designation requires manufacturers to demonstrate safety and clinical performance to a correspondingly rigorous standard, including independent notified-body review. For patients, this means the product has passed a structured regulatory scrutiny process, not merely a self-declaration of conformity. It does not guarantee outcomes in an individual case, but it does place the evidence bar meaningfully higher than lower-class device categories.

Procedural risks of the injection itself

Delivered as an ultrasound-guided outpatient injection, ChondroFiller® requires no general anaesthetic, no surgical incision, and no hospital admission. Patients attend a focused in-clinic appointment; the collagen scaffold is placed under real-time ultrasound guidance into the joint space, and they leave the same day. This delivery route carries a substantially lower procedural risk profile than the arthroscopic or open surgical pathways described in some of the external literature — the current London Cartilage Clinic service is the injectable pathway only.

Two concrete steps within the LCC protocol directly address the principal procedural risks. First, intravenous antibiotic prophylaxis is included as standard, providing cover against the infection risk that accompanies any intra-articular procedure. Second, a six-week follow-up appointment is built into the package, giving the clinical team an early window to monitor the initial response and identify any adverse reaction before it becomes established.

One honest limitation of the current evidence base should be noted: the available CER summary does not enumerate the frequency of specific post-injection adverse events such as temporary pain flare, effusion, or partial scaffold displacement. These events are not prominently flagged in the published data, but the absence of enumerated frequencies is itself a data gap rather than a confirmed absence of those events. Patients should raise questions about these possibilities directly in consultation, where individual history and defect characteristics can be factored into the conversation.

Why no early pain relief does not mean failure

The most common misread in ChondroFiller recovery is feeling no early pain relief and concluding the treatment has not worked. That inference is understandable but clinically incorrect — and acting on it, whether through premature repeat injection or abandoning the pathway, carries its own risks.

The mechanism explains why. Acellular matrix-induced chondrogenesis depends on the patient's own progenitor cells migrating into the collagen scaffold and remodelling it into functional tissue. There is no pharmacological analgesic effect. That biological process takes weeks to months; published outcome data for ChondroFiller reflect three-year endpoints, not post-procedure days — the Jerosch prospective PMCF study, for instance, measured sustained functional improvement at three years, not at six weeks.

This reframes the six-week review — already built into the pathway — as something more than a safety checkpoint. It becomes a structured moment for distinguishing slow responders, still within the biological repair window, from genuine non-responders who may need reassessment and a different clinical decision. That review also anchors what a genuine non-response looks like, which matters practically: a minority of patients do not achieve the expected level of cartilage regeneration, and surrounding cartilage quality, defect characteristics, and untreated mechanical instability all influence individual outcomes. The evidence-supported benefit profile is real, but it is not universal, and patients benefit from holding that honest framing from the outset.

Factors that affect outcomes — and who may not be suitable

Pre-treatment imaging review sets the clinical conditions for safe, appropriately dosed treatment — it is not an administrative step or a cost-generating formality.

The dosing is directly MRI-dependent. ChondroFiller® is supplied in 2.3 mL boxes, and the treating clinician selects one, two, or three based on defect dimensions measured on pre-treatment imaging. A consultation that produces a price estimate without having reviewed current MRI cannot accurately specify how many boxes are required — which means it cannot accurately specify the treatment itself.

The more clinically significant finding from that imaging assessment is whether mechanical instability is present. Ligament insufficiency or joint malalignment left untreated before injection is the single factor most consistently identified in published data as undermining ChondroFiller® outcomes; it functions in practice as a contraindication. The collagen scaffold cannot compensate for abnormal joint loading, and placing it in an unstable environment risks poor progenitor-cell migration and inadequate scaffold remodelling.

Outcome variability also reflects defect location and surrounding cartilage quality. The strongest evidence base sits with the knee — the Jerosch PMCF series followed knee patients to three years with defined functional outcome measures. For the ankle, hip, and small joints, published series are smaller and follow-up periods shorter. That matters practically: for joints other than the knee, realistic expectations should be discussed individually in consultation, since it is not safe to assume that knee-derived outcome figures transfer directly to a different joint anatomy or defect pattern.

Where combination with another intra-articular therapy is being considered, the rationale and sequencing should be agreed with the treating clinician rather than assumed as a standard add-on.

What to raise at your consultation

Four questions are worth raising explicitly before the injection takes place:

• Allergy history. ChondroFiller® is derived from murine collagen; any known sensitivity to rodent or animal proteins should be disclosed at the outset, not noted as an afterthought on the day.
• MRI findings and dosing. Ask what the imaging shows about defect dimensions and how many boxes have been determined as a result — dosing is imaging-dependent, and the treatment cannot be fully planned without a reviewed scan.
• Mechanical factors. Confirm that ligament stability and joint alignment have been assessed; as the evidence consistently shows, untreated instability is the single factor most reliably associated with a poor outcome.
• Post-injection expectations and review timing. Knowing when the six-week follow-up is scheduled anchors the recovery window and sets a structured point for reassessment if early response is slow.

As the evidence base continues to mature — long-term independent trial data remain limited — individual risk is best explored in conversation with a specialist rather than inferred from published aggregates alone.

To arrange a specialist cartilage assessment at London Cartilage Clinic, visit londoncartilage.com.